A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 22 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary) ; Olaparib (Primary) ; Bevacizumab; Doxorubicin liposomal; Gemcitabine; Paclitaxel; Topotecan
Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms COCOS

Most Recent Events

16 Jul 2024 Planned End Date changed from 30 Jun 2025 to 12 Jul 2025.
15 Jul 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
28 Jul 2023 Primary endpoint (Progression-free survival (PFS) (Phase II and Phase III)) has not been met, according to an AstraZeneca media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight